DAPK3 and non-small cell lung carcinoma: Previous reports have revealed that VIRMA-directed m6A modification promotes NSCLC progression through m6A-dependent degradation of DAPK3 and that VIRMA could become a new therapeutic target for NSCLC (Xu et al. 2021).